Saturday, 31 October 2026European Markets

PROACTIS SA Stock Bullish Momentum With A 9.17% Jump Before The Weekend

Loading stream...

(vianews) - the market ended the session with proactis sa (proac.pa) jumping 9.17% to €0.07 on friday, following the last session's downward trend. cac 40 jumped 0.7% to €7,966.68, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

proactis sa's last close was €0.06, 53.85% below its 52-week high of €0.13.

about proactis sa

proactis sa provides source-to-pay software solution. it operates software platform that will give control over business spend. it also offers procurement solutions that provide purchasing professionals with the tools they need for purchasing process for routine goods and services, capital goods, and major projects. in addition, it offers invoice capture services, system administration, supplier onboarding, and tail spent management services. further, its solutions integrate with various erp or financial systems. the company was formerly known as hubwoo and changed its name to proactis sa in january 2019. the company is based in suresnes, france. proactis sa operates as a subsidiary of proactis euro hedgeco limited.

earnings per share

as for profitability, proactis sa has a trailing twelve months eps of €-0.01.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.88%.

moving average

proactis sa's value is under its 50-day moving average of €0.08 and way below its 200-day moving average of €0.09.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com